EFMC-ISMC Virtual Event 2020
Confirmed Plenary Speakers (to Date)
QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases
Dr Atwood CHEUNG
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States)
The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis
Dr Andrew DILGER
(BRISTOL-MYERS SQUIBB, Princeton, United States)
First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases
Dr Riccardo GIOVANNINI
(BOEHRINGER INGELHEIM, Biberach, Germany)
Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other
Dr Uwe GRETHER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)
The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations
Dr Wooseok HAN
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South)
Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH
Dr Naoyoshi NOGUCHI
(SCOHIA PHARMA, INC., Fujisawa, Japan)
Discovery of AZD8154, a Dual PI3Kγδ Inhibitor, as an Inhaled Treatment for Asthma
Dr Matthew W. D. PERRY
(ASTRAZENECA, Gothenburg, Sweden)
Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy
Dr Norbert SCHMEES
(BAYER PHARMACEUTICALS, Berlin, Germany)
GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)
Dr Fredrik ZETTERBERG
(GALECTO BIOTECH, Gothenburg, Sweden)
Confirmed Speakers
Monday 07/09/2020
EFMC-ISMC Virtual Event 2020 - Day 1
17:00Opening Address by EFMC President
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
17:10Session Chair
Prof. Karl-Heinz ALTMANN
(ETH ZÜRICH, Zürich, Switzerland)
17:15Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy
Dr Norbert SCHMEES
(BAYER PHARMACEUTICALS, Berlin, Germany)
17:45Discovery of AZD8154, a Dual PI3Kγδ Inhibitor, as an Inhaled Treatment for Asthma
Dr Matthew W. D. PERRY
(ASTRAZENECA, Gothenburg, Sweden)
18:15The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis
Dr Andrew DILGER
(BRISTOL-MYERS SQUIBB, Princeton, United States)
18:45QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases
Dr Atwood CHEUNG
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States)
19:15Closing Remarks
Prof. Karl-Heinz ALTMANN
(ETH ZÜRICH, Zürich, Switzerland)
19:20End of Day 1
Tuesday 08/09/2020
EFMC-ISMC Virtual Event 2020 - Day 2
16:00Opening Address by EFMC-ISMC Chairman
Prof. Karl-Heinz ALTMANN
(ETH ZÜRICH, Zürich, Switzerland)
16:10Session Chair
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
16:15Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH
Dr Naoyoshi NOGUCHI
(SCOHIA PHARMA, INC., Fujisawa, Japan)
16:45The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations
Dr Wooseok HAN
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South)
17:15GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)
Dr Fredrik ZETTERBERG
(GALECTO BIOTECH, Gothenburg, Sweden)
17:45First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases
Dr Riccardo GIOVANNINI
(BOEHRINGER INGELHEIM, Biberach, Germany)
18:15Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other
Dr Uwe GRETHER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)
18:45Closing Remarks, EFMC-ISMC 2021 and EFMC Events
Prof. Karl-Heinz ALTMANN (ETH ZÜRICH, Zürich, Switzerland)
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
19:00End of the EFMC-ISMC Virtual Event 2020

Copyright 2022 LD Organisation srl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys